USPTO Examiner AULAKH CHARANJIT - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19054180GLP-1R AGONIST COMPOUND AND USE THEREOFFebruary 2025June 2025Allow410YesNo
18980700THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAFDecember 2024June 2025Allow710NoNo
18951509PLEUROMUTILIN ONIUM SALT DERIVATIVE CONTAINING A 3H-IMIDAZO[4,5-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOFNovember 2024January 2025Allow210NoNo
18854563RUTHENIUM PRECURSOR COMPOSITION, PREPARATION METHOD THEREFOR, AND FORMATION METHOD FOR RUTHENIUM-CONTAINING FILM USING SAMEOctober 2024February 2025Allow400NoNo
18762532HETEROCYCLIC GLP-1 AGONISTSJuly 2024August 2024Allow200NoNo
18669184TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOFMay 2024June 2025Abandon1310NoNo
18644945TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORSApril 2024May 2025Allow1300NoNo
18635402INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7)April 2024May 2025Abandon1310NoNo
18617266APOL1 INHIBITORS AND METHODS OF USEMarch 2024February 2025Allow1110NoNo
18604314THERAPEUTIC COMPOUNDSMarch 2024May 2025Allow1411YesNo
18443447METHODS AND COMPOSITIONS FOR MAINTAINING OPIOID EFFICACY IN THE TREATMENT OF PAINFebruary 2024April 2025Allow1420YesNo
18442788PYRROLO[2,3-C][2,6]NAPHTHYRIDINE-8-CARBOXYLIC ACIDS AS CK2 INHIBITORSFebruary 2024July 2024Allow510NoNo
18435998PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USEFebruary 2024February 2025Allow1210NoNo
18434637IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRAZINES AS CK2 INHIBITORSFebruary 2024August 2024Allow710NoNo
18433717COMPOUNDS, COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1120YesNo
18414429PYRAZOLO[4,3-C][2,6]NAPHTHYRIDINES AS CK2 INHIBITORSJanuary 2024April 2024Allow310NoNo
18409989PYRIDO[4,3-e]PYRROLO[1,2-a]PYRIMIDINE AS CK2 INHIBITORSJanuary 2024April 2024Allow300YesNo
18407001IMIDAZO[1,2-C]PYRIDO[3,4-E]PYRIMIDINE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORSJanuary 2024March 2024Allow200YesNo
183961982-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-3-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023February 2024Allow200NoNo
18394421ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)December 2023August 2024Allow700NoNo
18392204INHIBITORS OF KINASE NETWORKS AND USES THEREOFDecember 2023March 2025Allow1511NoNo
18391039PYRAZOLO[4,3-C][1,6]NAPHTHYRIDINES AS CK2 INHIBITORSDecember 2023February 2024Allow200YesNo
18543151Functionalized Heterocycles as Antiviral AgentsDecember 2023October 2024Allow1010NoNo
18543599OXAZOLE TRPML1 AGONISTS AND USES THEREOFDecember 2023May 2024Allow510NoNo
18543272SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDSDecember 2023November 2024Allow1010NoNo
18535055BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUESDecember 2023June 2025Allow1821NoNo
18515743TREATING PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHYNovember 2023January 2025Allow1420NoNo
18512473PROTEIN TYROSINE PHOSPHATASE INHIBITORSNovember 2023January 2025Allow1430NoYes
18511344FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOFNovember 2023January 2025Allow1410NoNo
18510120DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASESNovember 2023March 2025Allow1610NoNo
18386231MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCERNovember 2023March 2024Allow411NoNo
18386198MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCERNovember 2023March 2024Allow410NoNo
18386139INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRINNovember 2023April 2025Allow1711NoNo
18494550COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSOctober 2023July 2024Allow920NoNo
18493667CRYSTALLINE FORMS OF CFTR MODULATORSOctober 2023January 2025Allow1500NoNo
18484259ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSOctober 2023June 2025Abandon2011NoNo
18377633AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORSOctober 2023May 2025Allow2010NoNo
18376525SMALL MOLECULE INHIBITORS TARGETING CLOSTRIDIOIDES DIFFICILE SPORULATIONOctober 2023July 2024Allow1000YesNo
18475489Crystal and Amorphous Form of Tolebrutinib, Preparation Method Therefor, and Use ThereofSeptember 2023March 2024Allow510NoNo
183707427-(4-((4-BENZYLIDENE-5-OXO-2-PHENYL-4,5-DIHYDRO-1H-IMIDAZOL-1-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDSeptember 2023November 2023Allow200NoNo
18369537INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRINSeptember 2023July 2024Allow1000YesNo
18369071METHODS OF TREATING NEUROEPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORSSeptember 2023January 2025Allow1610NoNo
182414277-(4-((5-(3-BROMOBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDSeptember 2023February 2024Allow610NoNo
18239842COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASESAugust 2023October 2024Allow1310NoNo
182400122,6-DISUBSTITUTED PYRIDINE DERIVATIVEAugust 2023January 2025Abandon1610NoNo
18237535TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORSAugust 2023August 2024Allow1210NoNo
18237273ETHYL 2-SUBSTITUTED-1-(SUBSTITUTEDBENZOYL)-7-METHYLPYRROLO[1,2-a]QUINOLINE-3-CARBOXYLATE DERIVATIVES AS ANTI-TUBERCULAR AGENTSAugust 2023January 2024Allow510NoNo
18230585ADENOSINE RECEPTOR ACTIVITY OF METHYL/ETHYL 3-(SUBSTITUTED BENZOYL)-6,8-DIMETHYLINDOLIZINE-2-SUBSTITUTED-1-CARBOXYLATESAugust 2023March 2024Allow730YesNo
18272252KIFUNENSINE DERIVATIVESJuly 2023February 2024Allow710NoNo
18220484SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOFJuly 2023August 2024Allow1410NoNo
18349336Arginase Inhibitors and Methods of Use ThereofJuly 2023November 2023Allow410NoNo
18217084MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCERJune 2023October 2023Allow301YesNo
18217009TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOFJune 2023September 2023Allow310NoNo
18217037TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOFJune 2023September 2023Allow1510NoNo
16767155NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOFJune 2023November 2024Allow5420NoNo
18330932PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONEJune 2023November 2023Allow521YesNo
18205877METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDSJune 2023June 2024Allow1200NoNo
18319585HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOFMay 2023August 2024Allow1511NoNo
18319287SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOFMay 2023May 2025Allow2410NoNo
18143781MULTIVARIATE METAL-ORGANIC FRAMEWORKS FOR FINE-TUNING LIGHT EMISSIONMay 2023November 2024Allow1811NoNo
18142263PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAMEMay 2023March 2024Abandon1010NoNo
18138817COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASESApril 2023July 2023Allow300YesNo
18306710MORPHINAN COMPOUNDSApril 2023January 2025Allow2110NoNo
18302995Tetradentate Metal Complexes with Carbon Group Bridging LigandsApril 2023December 2024Allow1921YesNo
18132777Pan-Tropic Entry InhibitorsApril 2023December 2024Allow2010NoNo
18296543NOVEL DIZOCILPINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTSApril 2023December 2024Allow2010NoNo
18194678METHOD OF CONTROLLING DEPRESSION IN SUBJECTS TREATED FOR OPIOID DEPENDENCEApril 2023October 2024Allow1810NoNo
18187430EGFR INHIBITORSMarch 2023October 2024Allow1910NoNo
18182287BODIPY-BASED RHOMBIC METAL RING, PREPARATION METHOD THEREOF, AND APPLICATION IN NEAR-INFRARED REGION IMAGINGMarch 2023May 2023Allow200NoNo
18025017GROUP 4 METAL ELEMENT-CONTAINING COMPOUND, PRECURSOR COMPOSITION INCLUDING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAMEMarch 2023March 2025Allow2411NoNo
18111421Methods for Treating Huntington's DiseaseFebruary 2023October 2024Abandon2001NoNo
18110126CAPSID INHIBITORS FOR THE TREATMENT OF HIVFebruary 2023April 2024Allow1400NoNo
18169660NONMUSCLE MYOSIN II INHIBITORSFebruary 2023October 2024Allow2010NoNo
18166346QUINOLINE-2,3-FUSED NINE-MEMBERED RING SCAFFOLD COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF AS EFFECTIVE COMPONENT IN PLANT FUNGICIDEFebruary 2023September 2023Allow720NoNo
18103662JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASEJanuary 2023July 2024Allow1810NoNo
18103173LIQUID PHARMACEUTICAL FORMULATIONS OF APIXABANJanuary 2023July 2023Allow610YesNo
18100992SPIROCYCLIC COMPOUNDSJanuary 2023September 2024Allow2011NoNo
18098070APOL1 INHIBITORS AND METHODS OF USEJanuary 2023November 2023Allow1010NoNo
18096996AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORSJanuary 2023August 2023Allow811NoNo
18068951IRAK DEGRADERS AND USES THEREOFDecember 2022January 2025Allow2510NoNo
18067384HETEROCYCLIC RIP1 INHIBITORY COMPOUNDSDecember 2022October 2024Abandon2210NoNo
18064952Pt-xanthene-iodine complex and Pt-xanthene-bromine complexDecember 2022October 2023Allow1020NoNo
18065219SMAD4 Complex Inducers and Uses in Cancer TherapyDecember 2022June 2024Abandon1820YesNo
18060456MASP-2 INHIBITORS AND METHODS OF USENovember 2022August 2024Allow2111NoNo
18060098FASORACETAM CRYSTALLINE FORMSNovember 2022May 2024Allow1810NoNo
17927324HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOFNovember 2022February 2024Allow1500NoNo
17990133ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOFNovember 2022July 2024Allow2010NoNo
17918135TRICYCLIC PESTICIDAL COMPOUNDSOctober 2022June 2025Allow3200NoNo
17962187HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOFOctober 2022December 2024Abandon2610NoNo
17962346DOPAMINE D2 RECEPTOR LIGANDSOctober 2022May 2025Allow3131YesNo
17961270ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITIONOctober 2022September 2024Allow2310NoNo
17957103ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVESeptember 2022June 2024Allow2010NoNo
17957350TREATMENT OF DEMYELINATING DISEASESSeptember 2022February 2025Allow2820NoNo
17933213MONOCARBORANE CLUSTER -CONTAINING PLATINUM COMPLEXES AND PREPARATION METHOD AND OLED APPLICATIONSeptember 2022August 2023Allow1100NoNo
17932705TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUESSeptember 2022October 2024Allow2521YesNo
17946129ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICESSeptember 2022June 2024Allow2111YesNo
17931801DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORSSeptember 2022November 2024Allow2620NoNo
17944060TETRAHYDROISOQUINOLINE DERIVATIVESSeptember 2022March 2024Allow1800NoNo
17942555MORPHINAN COMPOUNDSSeptember 2022July 2024Abandon2210NoNo
17823910CARDIAC SARCOMERE INHIBITORSAugust 2022April 2024Allow1901YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AULAKH, CHARANJIT.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.1%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
51
Allowed After Appeal Filing
30
(58.8%)
Not Allowed After Appeal Filing
21
(41.2%)
Filing Benefit Percentile
87.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 58.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner AULAKH, CHARANJIT - Prosecution Strategy Guide

Executive Summary

Examiner AULAKH, CHARANJIT works in Art Unit 1621 and has examined 1,092 patent applications in our dataset. With an allowance rate of 93.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 20 months.

Allowance Patterns

Examiner AULAKH, CHARANJIT's allowance rate of 93.9% places them in the 82% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AULAKH, CHARANJIT receive 1.20 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AULAKH, CHARANJIT is 20 months. This places the examiner in the 87% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +1.3% benefit to allowance rate for applications examined by AULAKH, CHARANJIT. This interview benefit is in the 16% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 37.9% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 79.5% of cases where such amendments are filed. This entry rate is in the 95% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 142.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 87% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 98.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.2% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 17.1% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.